CRISPR Therapeutics AG
Every calculator, already run for CRSP
Open the full toolkit →You have the numbers on CRSP. Get the argument.
A written report on which of these readings actually decide the outcome for CRISPR Therapeutics AG, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
22 analysts covering CRSPAnalyst Price Target Disagreement for CRISPR Therapeutics AG
Wall Street's bull case implies +414% from the current price; the bear case implies -22%. A 437% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for CRSP
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for auto…
CRSP — frequently asked
Is CRSP a buy right now?
Wall Street's consensus rating on CRISPR Therapeutics AG is Buy across 22 analysts, with a mean price target of $87.56 (+55% vs. the current $56.56). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is CRSP's next earnings date?
CRISPR Therapeutics AG is next scheduled to report earnings around Nov 9, 2026. A full CRSP research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for CRISPR Therapeutics AG?
Analysts covering CRISPR Therapeutics AG (CRSP) range from a bear-case target of $44.00 to a bull-case high of $291.00, with a mean consensus target of $87.56 across 18 analysts. The spread of $247.00 (437% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare CRISPR Therapeutics AG against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For CRISPR Therapeutics AG
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CRSP research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on CRISPR Therapeutics AG, in minutes. 3 free reports included with every account — no credit card required.